Union Health Ministry has recommended use of anti-HIV drug combinations Lopinavir and Ritonavir on a case-to-case basis depending upon the severity of the condition of a patient having coronavirus infection. In its revised guidelines on the ‘Clinical Management of COVID – 19’ issued on Tuesday, the ministry recommended Lopinavir-Ritonavir for high-risk groups patients aged above 60, suffering from diabetes mellitus, renal failure, chronic lung disease and are immuno – compromised.
According to a health ministry official, a committee of experts comprising doctors from AIIMS, experts from National Centre for Disease Control (NCDC) and WHO among others revisited the treatment guidelines and recommended supportive treatment in patients suffering from coronavirus infection.
The ministry also recommended Lopinavir-Ritonavir for symptomatic patients having hypoxia, hypotension, new onset organ dysfunction (one or more), increase in creatinine by 50 per cent from baseline and any other organ dysfunction among others. There is no current evidence from randomised controlled trial to recommend any specific treatment for suspected or confirmed patients with COVID-19.
Post Your Comments